3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
3
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Mantle-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
Rituximab
49
fludarabine phosphate
32
Cyclophosphamide
30
Whole-Body Irradiation
26
Peripheral Blood Stem Cell Transplantation
25
Mycophenolic Acid
24
Tacrolimus
19
Cyclosporine
16
Dexamethasone
13
Busulfan
13
ibrutinib
12
Sirolimus
12
Bortezomib
11
Antilymphocyte Serum
11
Melphalan
10
Etoposide
10
Calcium Dobesilate
10
Methotrexate
8
Lenalidomide
8
Cyclosporins
8
idelalisib
7
Everolimus
6
Indium
5
Filgrastim
5
thymoglobulin
4
ibritumomab tiuxetan
4
carfilzomib
4
Vincristine
4
Prednisone
4
In Situ Hybridization, Fluorescence
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Waldenstrom Macroglobulinemia
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts